{"id":888225,"date":"2025-09-22T08:38:26","date_gmt":"2025-09-22T12:38:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/"},"modified":"2025-09-22T08:38:26","modified_gmt":"2025-09-22T12:38:26","slug":"gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/","title":{"rendered":"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025<\/b><\/p>\n<p class=\"bwalignc\">\n&#8211; One Oral and Four Poster Presentations Highlight Seralutinib\u2019s Potential Across Pulmonary Hypertension and Fibrotic Lung Disease &#8211;<\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gossamerbio.com%2F&amp;esheet=54327225&amp;newsitemid=20250922224756&amp;lan=en-US&amp;anchor=Gossamer+Bio%2C+Inc.&amp;index=1&amp;md5=03ced597d4adc8793fa624dafb11418b\">Gossamer Bio, Inc.<\/a> (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27<sup>th<\/sup> through October 1<sup>st<\/sup> in Amsterdam, Netherlands and online. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.<\/p>\n<p><b>ERS 2025 Presentation Details:<\/b><\/p>\n<p><b>Session Type: <\/b>Oral Presentation<br \/>\n<br \/><b>Session Title: <\/b>From omics to targets: emerging insights into chronic pulmonary disease mechanisms (Session 94)<br \/>\n<br \/><b>Session Date &amp; Time: <\/b>September 28<sup>th<\/sup>, 9:30am \u2013 10:45am CEST<br \/>\n<br \/><b>Location: <\/b>Amtrium<br \/>\n<br \/><b>Abstract Number: <\/b>OA1201<br \/>\n<br \/><b>Presentation Title: <\/b>Seralutinib targets fibrotic pathways in IPF: Evidence from single\u2011cell transcriptomics<br \/>\n<br \/><b>Presenter: <\/b>Dr. Rui Benfeitas (Chiesi Group)<\/p>\n<p><b>Session Type: <\/b>Poster Presentation<br \/>\n<br \/><b>Session Title: <\/b>Preclinical insights into rare diseases (Session 75)<br \/>\n<br \/><b>Session Date &amp; Time: <\/b>September 28<sup>th<\/sup>, 8:00am \u2013 9:30am CEST<br \/>\n<br \/><b>Location: <\/b>PS-7<br \/>\n<br \/><b>Abstract Number: <\/b>PA1039<br \/>\n<br \/><b>Presentation Title: <\/b>Seralutinib demonstrates <i>in vitro<\/i> reduction of vascular inflammatory drivers underlying pulmonary hypertension<br \/>\n<br \/><b>Presenter: <\/b>Dr. Zhaoqing Ding (Gossamer Bio)<\/p>\n<p><b>Session Type: <\/b>Poster Presentation<br \/>\n<br \/><b>Session Title: <\/b>Translational studies in interstitial lung disease of known causes (Session 149)<br \/>\n<br \/><b>Session Date &amp; Time: <\/b>September 28<sup>th<\/sup>, 12:30pm \u2013 2:00pm CEST<br \/>\n<br \/><b>Location: <\/b>PS-34<br \/>\n<br \/><b>Abstract Number: <\/b>PA1864<br \/>\n<br \/><b>Presentation Title: <\/b>Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models<br \/>\n<br \/><b>Presenter: <\/b>Dr. Ravikumar Sitapara (Gossamer Bio)<\/p>\n<p><b>Session Type: <\/b>Poster Presentation<br \/>\n<br \/><b>Session Title: <\/b>Pulmonary arterial hypertension: risk assessment and impact of current and newly developed treatments (Session 423)<br \/>\n<br \/><b>Session Date &amp; Time: <\/b>September 30<sup>th<\/sup>, 8:00am \u2013 9:30am CEST<br \/>\n<br \/><b>Location: <\/b>PS-38<br \/>\n<br \/><b>Abstract Number: <\/b>PA5143<br \/>\n<br \/><b>Presentation Title: <\/b>Seralutinib increases small pulmonary artery vessel volume and reduces vessel wall remodeling: Insights from AI-driven CT imaging analysis<br \/>\n<br \/><b>Presenter: <\/b>Dr. Ra\u00fal San Jos\u00e9 Est\u00e9par (Brigham Women\u2019s Hospital)<\/p>\n<p><b>Session Type: <\/b>Poster Presentation<br \/>\n<br \/><b>Session Title: <\/b>Pulmonary arterial hypertension: risk assessment and impact of current and newly developed treatments (Session 423)<br \/>\n<br \/><b>Session Date &amp; Time: <\/b>September 30<sup>th<\/sup>, 8:00am \u2013 9:30am CEST<br \/>\n<br \/><b>Location: <\/b>PS-38<br \/>\n<br \/><b>Abstract Number: <\/b>PA5144<br \/>\n<br \/><b>Presentation Title: <\/b>Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an <i>in vitro<\/i> model of pulmonary fibrosis<br \/>\n<br \/><b>Presenter: <\/b>Dr. Zhaoqing Ding (Gossamer Bio)<\/p>\n<p><b>About Gossamer Bio<\/b><\/p>\n<p>\nGossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250922224756\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250922224756\/en\/<\/a><\/span><\/p>\n<p><b>For Investors and Media<br \/>\n<\/b><br \/>Bryan Giraudo, Chief Operating Officer and Chief Financial Officer<br \/>\n<br \/>Gossamer Bio Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@gossamerbio.com\">ir@gossamerbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States Netherlands North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Genetics Research Science Pharmaceutical Cardiology Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250922224756\/en\/818570\/3\/GossamerBio-Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 &#8211; One Oral and Four Poster Presentations Highlight Seralutinib\u2019s Potential Across Pulmonary Hypertension and Fibrotic Lung Disease &#8211; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th through October 1st in Amsterdam, Netherlands and online. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement. ERS 2025 Presentation Details: Session &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-888225","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 &#8211; One Oral and Four Poster Presentations Highlight Seralutinib\u2019s Potential Across Pulmonary Hypertension and Fibrotic Lung Disease &#8211; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th through October 1st in Amsterdam, Netherlands and online. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement. ERS 2025 Presentation Details: Session &hellip; Continue reading &quot;Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-22T12:38:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025\",\"datePublished\":\"2025-09-22T12:38:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/\"},\"wordCount\":507,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/\",\"name\":\"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-09-22T12:38:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/","og_locale":"en_US","og_type":"article","og_title":"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Market Newsdesk","og_description":"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 &#8211; One Oral and Four Poster Presentations Highlight Seralutinib\u2019s Potential Across Pulmonary Hypertension and Fibrotic Lung Disease &#8211; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th through October 1st in Amsterdam, Netherlands and online. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement. ERS 2025 Presentation Details: Session &hellip; Continue reading \"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-22T12:38:26+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025","datePublished":"2025-09-22T12:38:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/"},"wordCount":507,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/","name":"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-09-22T12:38:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250922224756r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-presentations-at-the-european-respiratory-society-ers-congress-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=888225"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888225\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=888225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=888225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=888225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}